Corinne Gonzalez (Toulouse, France)

Advantages:

Effective, efficiency – Good functional results, better than usual treatments – more retinal protective, no grid laser scars – less recurrences.

Methods:

12 eyes of 12 patients, 10 men, 2 women, with Type 1 idiopathic macular telangiectasia. Patients received intravitreal Ranibizumab, 3 times, every 4 weeks. The next injections (IVR) depended on the follow-up results and were done by series of 3. First and 2 months’ interval follow-up exam included ETDRS visual acuity (VA), complete ophthalmic examination, fluorescein (FA) angiography, and optical coherence tomography (OCT). VA and OCT were done before each IVT. We want to evaluate the incidence of this protocol on the exudation and frequency of recurrence of exudation and so on the number of IVR needed.

Effectiveness / Safety:

VA improved in 85% cases, stabilized in 15%. Angiographic leakage reduced 90% in 80% cases, cystic macular edema disappeared, telangiectasia’s size diminished. Diffuse edema was 80% reduced in 85%, total thickness was 45% less in the average follow-up, cysts 100% disappeared in 75% cases, in 30% were diminished in size, volume and number, by OCT. Most of patients had good functional, anatomical results, with few IVR needed, no scars in the retina. Inductive treatment was sufficient in 8 cases, needed added IVR in 4 cases, and failed in no cases. No bad side effects, no complications.

Take home message:

New approach for telangiectasies type 1 treatment.